肿瘤细胞治疗研究
英文原题：Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple Myeloma.
在本期《Blood Cancer Discovery》中，Merz及其同事研究了600多名接受CAR-T 细胞（CAR T）和/或双特异性抗体治疗的多发性骨髓瘤患者，重点关注序贯接受两种疗法的患者。
在本期《Blood Cancer Discovery》中，Merz及其同事研究了600多名多发性骨髓瘤患者，这些患者接受了CAR-T 细胞和/或双特异性抗体治疗；研究重点是先后接受这两种治疗的患者。研究发现，先采用CAR-T治疗可显著延长无进展生存期。值得注意的是，在先接受另一种治疗后疾病进展的患者中，两种治疗的结局相近，因此这一优势源于CAR-T治疗作为初始治疗时带来的获益。见Merz等人的相关文章，第697页。
In this issue of Blood Cancer Discovery, Merz and colleagues study more than 600 recipients of chimeric antigen receptor T-cell (CAR T) and/or bispecific antibody therapy in multiple myeloma with an emphasis on patients who received both modalities sequentially. They find a clear progression-free survival advantage when CAR T therapy was used first; importantly, because outcomes with both modalities were similar when following progression after the converse modality, this advantage was driven by CAR T therapy's up-front benefits. See related article by Merz et al, p. 697.
MEMBER ACCOUNT
登录成功会直接打开下一页。
